Chris E. Simmons

Array ( [id] => 20720957 [patent_doc_number] => 20260137656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-21 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS [patent_app_type] => utility [patent_app_number] => 19/446115 [patent_app_country] => US [patent_app_date] => 2026-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19446115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20720959 [patent_doc_number] => 20260137658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-21 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS [patent_app_type] => utility [patent_app_number] => 19/446133 [patent_app_country] => US [patent_app_date] => 2026-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19446133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20720958 [patent_doc_number] => 20260137657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-21 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS [patent_app_type] => utility [patent_app_number] => 19/446127 [patent_app_country] => US [patent_app_date] => 2026-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19446127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20584006 [patent_doc_number] => 20260069596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-12 [patent_title] => USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 19/391715 [patent_app_country] => US [patent_app_date] => 2025-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19391715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20554011 [patent_doc_number] => 20260053791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER [patent_app_type] => utility [patent_app_number] => 19/376086 [patent_app_country] => US [patent_app_date] => 2025-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19376086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20425277 [patent_doc_number] => 20250387364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-25 [patent_title] => ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN [patent_app_type] => utility [patent_app_number] => 19/308893 [patent_app_country] => US [patent_app_date] => 2025-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19308893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20393167 [patent_doc_number] => 20250368642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-04 [patent_title] => SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND [patent_app_type] => utility [patent_app_number] => 19/281019 [patent_app_country] => US [patent_app_date] => 2025-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19281019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20393168 [patent_doc_number] => 20250368643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-04 [patent_title] => SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND [patent_app_type] => utility [patent_app_number] => 19/281069 [patent_app_country] => US [patent_app_date] => 2025-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28374 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19281069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20348584 [patent_doc_number] => 20250345436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS [patent_app_type] => utility [patent_app_number] => 19/276294 [patent_app_country] => US [patent_app_date] => 2025-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19276294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20336449 [patent_doc_number] => 20250340569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => INHIBITORS OF KIF18A AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/272410 [patent_app_country] => US [patent_app_date] => 2025-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 203 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19272410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20335323 [patent_doc_number] => 20250339443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => METHOD FOR TREATING OR PREVENTING CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL OR DISCOIDIN DOMAIN RECEPTOR 2 RELATED DISORDERS OR CONDITIONS [patent_app_type] => utility [patent_app_number] => 19/271829 [patent_app_country] => US [patent_app_date] => 2025-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19271829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20425269 [patent_doc_number] => 20250387356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-25 [patent_title] => MIRDAMETINIB TREATMENT [patent_app_type] => utility [patent_app_number] => 19/237417 [patent_app_country] => US [patent_app_date] => 2025-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19237417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20226293 [patent_doc_number] => 12414932 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Arsinothricin and methods of treating infections using arsinothricin [patent_app_type] => utility [patent_app_number] => 19/176900 [patent_app_country] => US [patent_app_date] => 2025-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 33 [patent_no_of_words] => 8356 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19176900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20093344 [patent_doc_number] => 20250223280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-10 [patent_title] => POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS [patent_app_type] => utility [patent_app_number] => 19/081912 [patent_app_country] => US [patent_app_date] => 2025-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 124037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19081912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20068513 [patent_doc_number] => 20250206735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-26 [patent_title] => SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND [patent_app_type] => utility [patent_app_number] => 18/987568 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18987568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19896375 [patent_doc_number] => 12274265 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-04-15 [patent_title] => Emulsifiable neonicotinoid pesticide concentrate [patent_app_type] => utility [patent_app_number] => 18/968074 [patent_app_country] => US [patent_app_date] => 2024-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 5252 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18968074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19890293 [patent_doc_number] => 20250115605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => AZAINDOLE ROCK INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/915221 [patent_app_country] => US [patent_app_date] => 2024-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18915221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19960257 [patent_doc_number] => 12329729 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-06-17 [patent_title] => Method of treating cancer in a subject [patent_app_type] => utility [patent_app_number] => 18/895223 [patent_app_country] => US [patent_app_date] => 2024-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5745 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809452 [patent_doc_number] => 12240822 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Naphthalene isoxazoline compound and application thereof [patent_app_type] => utility [patent_app_number] => 18/820199 [patent_app_country] => US [patent_app_date] => 2024-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 6426 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18820199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570264 [patent_doc_number] => 20240374556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/782646 [patent_app_country] => US [patent_app_date] => 2024-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18782646 [rel_patent_id] =>[rel_patent_doc_number] =>)